Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Dosing Duration" patented technology

Operation Of A Remote Medication Management System

An integrated medication management and compliance system for enabling a care provider to remotely manage and deliver individual doses of medications to a patient, in a non-sequential fashion. The system includes delivery apparatus remotely located from the care provider, wherein the apparatus stores a plurality of sealed unit dose packages that are delivered to a patient at a scheduled dosing time. The delivery apparatus is coupled to a control facility and to a computer terminal of the care provider by way of a secure communications network. The system enables the patient's medication regimen to be remotely tailored in real-time to accommodate fluid medical conditions.
Owner:INRANGE SYSTEMS INC (A DELAWARE CORPORATION)

Asymmetric dosing methods

InactiveUS20060287248A1BiocideDipeptide ingredientsHcv hepatitis c virusDosing Duration
A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an asymmetric pattern as to dosage amount and / or timing of dosage, wherein the at least one compound is selected from the group consisting of compounds of Formulae I-XXVI, described herein. Methods of modulating the activity of hepatitis C virus protease in a subject are also provided. Asymmetric dosing as to amount of dose and / or timing of dose permits adjustment of dosing to accommodate variations in drug metabolism and / or viral activity caused by viral cell division or a patient's circadian rhythms, thus delivering the maximum amount of dose at the time or times it is most effective.
Owner:SCHERING CORP

Method and composition to evaluate cytochrome P450 2D6 isoenzyme activity using a breath test

The present invention relates, generally to a method of determining and assessing cytochrome P450 2D6 isoenzyme (CYP2D6)-related metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by a the subject upon intravenous or oral administration of a 13C-labeled CYP2D6 substrate compound. The present invention is useful as an in vivo phenotype assay for evaluating CYP2D6-related activity using the metabolite 13CO2 in expired breath and to determine the optimal dosage and timing of administration of CYP2D6 substrate compound.
Owner:OTSUKA AMERICA PHARMA INC

Medication dosage reminder device

A medication dosage reminder device (100) operating on the exterior wall surface of a medication container (C) includes a band support (110) on the wall and a flexible band (132) continuously mounted (132m) closely around the wall of the container, above the band support. A single device is suitable for a large variety of common medication container shapes and sizes. Mating contact areas (112) (136), on the two members limit movement of the mounted band when they are selectively engaged. The mounted band is otherwise free to rotate about the container. Co-operating indicia on the device include an indicator pointer (138) and dosage time periods (120) that may be inscribed (122) to establish a highly customized dosage schedule. A patient rotates the band to indicate the next scheduled dosage time period. The indicator pointer and the scheduled dosage time period form a reminder indicating when the next dose is due or when the last dose was taken.
Owner:GIEWERCER HARRY

Dosage reminder device and medication carton

InactiveUS20030029374A1Identification meansCartonDosage schedule
A dosage reminder device (100) and medication carton (130) includes an indicator / support (140) formed from the carton's flat exterior wall (132) retentively engaging a rotateable ring (110). The ring includes dosage time period indicia (118) establishing (120) a dosage schedule and the indicator includes a co-operating next dose pointer (146) for selecting the next dosage time period so indicated. A patient can rotate the ring to align the next scheduled dosage time period with the indicator pointer. The indicator pointer and the scheduled dosage time period form a reminder indicating when the next dose is due or when the last dose was taken.
Owner:GIEWERCER HARRY

Fermentation with cyclic pulse-pause feeding

A process for the production of a valuable compound, comprising the steps of a) fermentation of a filamentous bacterial or fungal strain (e.g. a Streptomyces strain or an Aspergillus strain) in a fermentation medium wherein a carbohydrate during fermentation is added in a cyclic pulse dosing / pause way, wherein the pulse dosing time is shorter than the pause time and b) recovery of the valuable compound from the fermentation broth.
Owner:NOVOZYMES AS +2

Shikonin temperature-sensitive hydrogel and preparation method and application thereof

The present invention discloses a shikonin temperature-sensitive aseptic hydrogel, a preparation method and an application thereof, and belongs to the technical field of pharmaceutics. A hydrogel carrier does not use a crosslinking agent, which avoids damages to human body by the crosslinking agent. The preparation method is simple, experimental conditions are mild, no special equipment is needed,investment cost is low, used reagents are conventional reagents, and the shikonin temperature-sensitive hydrogel is convenient for industrial implementation and environmentally friendly. When the shikonin temperature-sensitive hydrogel is used for vaginal administration, the shikonin temperature-sensitive hydrogel has advantages of convenient administration, easy dosage control, uniform distribution, long administration time, etc.; and when the shikonin temperature-sensitive hydrogel is used for burnt skin or inflammatory and damaged skin or mucosal surfaces, the shikonin temperature-sensitive hydrogel has advantages of small stimulation to wound surfaces, easy spreading, uniform distribution, convenient administration, accurate dosage, etc. By loading main medicines and corresponding medicinal auxiliary materials, the shikonin temperature-sensitive hydrogel play moisturizing, repairing, disinfection, sterilization and therapeutic effects, at the same time can form a layer of protective film on surface of lesion, and realizes aseptic maintenance and wound protection for the lesion.
Owner:XI AN JIAOTONG UNIV

Atomizer control method, device, medium and system

ActiveCN114099883ANo false startNo false shutdownRespiratorsInhalatorsTreatment effectDosing Duration
The embodiment of the invention discloses an atomizer control method, device, medium and system, and the method comprises the steps: obtaining the pressure data of the pressure in the airway of a respiratory support device, and determining the pressure state of the pressure in the airway according to the pressure data; when the current pressure state is the rising edge state and the previous pressure state is the gentle area state, the working state of the atomizer is set to be the atomization starting state; and / or, in response to the current pressure state being the falling edge state and the previous pressure state being the gentle area state, the working state of the atomizer is set to be the atomization closed state. According to the scheme, mistaken starting or mistaken closing of the atomizer cannot be caused, most of liquid medicine atomized by the atomizer can be inhaled into the body by a target, and therefore it is guaranteed that the atomized liquid medicine cannot be wasted, the utilization rate of the liquid medicine is increased, and / or the time proportion of effective administration time in the whole respiratory cycle can be increased as much as possible, and the use effect of the atomizer is improved. Therefore, the treatment cost is reduced, and the treatment effect is improved.
Owner:SHENZHEN MOORE HEALTH MEDICAL TECH CO LTD

Drug sustained and controlled release platform system with dual nano composite structure

The invention provides a drug sustained and controlled release platform system with a double-nano composite structure in order to solve the problems that only one drug can be loaded in an existing drug delivery system, and the release rate of the drug cannot be effectively regulated and controlled due to the fact that several drugs are loaded into the same drug loading material. The nano-drug delivery system is used for in-vivo oral administration or in-vitro drug delivery, the same drug or different drugs can be respectively loaded into two nano-materials with different nano-structures in thesame drug delivery system, the specific surface area and the drug loading rate of the drug delivery system are further improved, the continuous drug delivery time of one-time drug delivery is prolonged, the drug delivery times of a patient are reduced, and the drug delivery efficiency is improved. The drug release speed can be respectively regulated and controlled, and the drug use accuracy is improved; the synergistic effect of the medicines is fully exerted, and the medicine sustained and controlled release function of the preparation material is fully exerted, so that a more ideal treatment effect is achieved.
Owner:YANCHENG INST OF TECH

Naru-3 cataplasma and preparation method thereof

The invention relates to naru-3 cataplasma and a preparation method thereof, and particularly relates to an external medicine for treating rheumatoid arthritis and a preparation method thereof. By adopting the dosage form, the efficient infiltration promotion property of a micro-emulsion, and the adhesiveness and the drug storage capacity of the cataplasma are simultaneously combined, the dosing duration is obviously prolonged when the transdermal absorption rate is increased, and the naru-3 cataplasma is high in biocompatibility on skin, ventilating, sweat-resistant and less in irritability.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Apparatuses and methods for setting an electrical dose

Methods and apparatuses for setting a therapeutic dose of a neuromodulator implanted into a patient are described. The therapeutic dose typically includes a therapeutic dose duration including a ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The methods and apparatuses described herein may use a testing ramp to identify a peak modulation voltage that is patient-specific and provides a maximized therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator.
Owner:NEUROS MEDICAL

A kind of cariprazine hydrochloride injection preparation and its preparation method and application

ActiveCN108261394BImprove drug stabilitySmall batch-to-batch variancePowder deliveryOrganic active ingredientsCariprazineDosage adjustment
The invention provides a cariprazine hydrochloride injection preparation and its preparation method and application. When the injection preparation is used, it is a suspension aqueous solution, wherein the concentration of cariprazine hydrochloride is relatively high, and the stability is good, and a higher dosage can be obtained in a limited injection volume, and it can also be used according to the long-acting administration time. The dose can be flexibly adjusted, and by controlling the particle size distribution and the injection dose, a long-acting effect can be achieved. After injection, the preparation can release cariprazine continuously for at least 1 week, and can be administered once a week or more. Long dosing intervals to increase patient compliance. The invention also provides a preparation method of the cariprazine hydrochloride injection preparation, the injection preparation prepared by the method has good stability and high safety, the method is simple and easy, and is suitable for industrial production.
Owner:SUNSHINE LAKE PHARM CO LTD

System and method for digitally translating natural language prescription medication label to programmatically operable structure for use with smart pill containers

A smart pill container and system integrating the same, combined with a method for digitally translating natural language prescription medication into a programmatically operable structure and form for use by the smart pill container system, where the digital translation includes the abstraction of a prescription frequency characteristic into a number of “slots” and the abstraction of a prescription temporary characteristic by creating an array of “as of” date and value pairs, allowing for the building of a patient's prescription schedule, where the smart pill container has a number of pill wells for storing different doses of medication, and where based on the prescription schedule, an opening in the pill container provides at least one user with access to the medication stored in a particular one of the pill wells at a given dosing time, and where a platform associated with the pill container provides instructions for dosing such medication and monitors use of the pill container for compliance with the prescribed medical regimen.
Owner:SHARP SOLUTIONS LLC

Method for establishing rat premature ovarian failure model by utilizing cisplatin

The invention discloses a method for establishing a rat premature ovarian failure model by utilizing cisplatin. The method comprises the following steps: applying the cisplatin with a dosage of 2-3 mg / Kg per day according to a body weight to a rat in an intraperitoneal injection mode, wherein the cisplatin application method is as follows: continuously applying the cisplatin for 7 days, and obtaining the rat premature ovarian failure model on the 15th day after the last injection; or applying the cisplatin with a dosage of 4-6 mg / Kg according to the body weight to the rat in an intraperitonealinjection mode, wherein the cisplatin application method is as follows: applying the cisplatin on the first day and the eighth day, and obtaining the rat premature ovarian failure model on the 15th day after the last injection. According to the invention, a chemotherapeutic injury premature ovarian failure animal model is established by using different concentrations of cisplatin and different application methods of the cisplatin; through comparison of advantages and disadvantages of the application methods of the cisplatin, the optimal concentration and administration time of the cisplatin are screened out; and an experimental method which is simple in operation, high in success rate and reliable in result is provided for establishing a stable premature ovarian failure animal model for basic research.
Owner:北京银丰鼎诚生物工程技术有限公司 +1

Programmable therapeutic agent delivery from eye mounted device

The present disclosure relates to relates to systems and methods for on-demand delivery of a therapeutic agent from an eye mounted device. Particularly, aspects of the present invention are directed to a method of delivering a therapeutic agent, the method including receiving, at a controller of a therapeutic agent release and delivery device, a first command signal for delivery of a therapeutic agent based on a dosing time window. Upon receipt of the first command signal, the controller determines whether one or more compliance conditions are satisfied. When the one or more conditions are satisfied, the controller initiate a release and delivery protocol that commands a signal generator to generate and send a second command signal causing a capacitor or one or more circuits to deliver an actuation signal causing one or more therapeutic agent delivery mechanisms to open and release the therapeutic agent from one or more reservoirs.
Owner:VERILY HEALTH INC

A method for controlling drug administration time

The present invention discloses a method for controlling drug administration time. The method for controlling drug administration time of the present invention comprises the following steps: S1: according to the drug administration time, drug administration amount and drug viscosity in a specific treatment scheme, the target permeability is calculated, that is, the product of the drug administration amount per unit time and the drug viscosity; S2: this step can be: Scheme 1: select a drug delivery device according to the target permeability, so that the deviation between the actual permeability of the drug delivery device and the target permeability is less than the allowable value; the actual permeability is the product of the volume of fluid exuded per unit time of the drug delivery device and the viscosity of the fluid; Scheme 2: determine the material, pore structure and pore distribution of the drug delivery device with a drug exudation area of ​​a microporous structure, adjust one or more of the porosity, pore size and number of pores of the drug delivery device, so that the deviation between the actual permeability of the drug delivery device and the target permeability is less than the allowable value; the actual permeability is the product of the volume of fluid exuded per unit time of the drug delivery device and the viscosity of the fluid.
Owner:YOUCHANGDA (WUHAN) MEDICAL TECH CO LTD

Dosing labels for electronic medication container caps

One example medication container includes a storage portion enclosing a volume to store medication and having an opening providing access to the volume, a cap configured to releasably couple to and seal the storage portion, the cap including one or more visual indicators; a sensor; and an electronic timer, wherein the sensor is configured to output a signal in response to detecting that the cap is decoupled from the storage portion; and the timer is configured to reset based on the signal and to output one or more signals to activate the one or more visual indicators based on an elapsed time since a most recent resetting of the timer and one or more thresholds; and a label affixed to the cap, the label having one or more markers, the one or more markers corresponding to the one or more visual indicators, the markers indicating dosing times associated with a medication.
Owner:VERILY LIFE SCIENCES LLC

Programmable therapeutic agent delivery from eye mounted device

The present disclosure relates to relates to systems and methods for on-demand delivery of a therapeutic agent from an eye mounted device. Particularly, aspects of the present invention are directed to a method of delivering a therapeutic agent, the method including receiving, at a controller of a therapeutic agent release and delivery device, a first command signal for delivery of a therapeutic agent based on a dosing time window. Upon receipt of the first command signal, the controller determines whether one or more compliance conditions are satisfied. When the one or more conditions are satisfied, the controller initiate a release and delivery protocol that commands a signal generator to generate and send a second command signal causing a capacitor or one or more circuits to deliver an actuation signal causing one or more therapeutic agent delivery mechanisms to open and release the therapeutic agent from one or more reservoirs.
Owner:TWENTY TWENTY THERAPEUTICS LLC

Method and apparatus for measuring a receding contact angle

A method for measuring a receding contact angle between a sample surface and a drop of a liquid is provided. The method includes ejecting a dosing volume of the liquid from an opening onto the sample surface such that the liquid is ejected as a continuous jet at a defined flow rate for a defined dosing time period, and the opening comprises an opening diameter. The dosing volume of the liquid is allowed to form a drop on the sample surface. At least one geometrical parameter of the drop formed on the sample surface is measured and a contact angle between the sample surface and the drop is determined based on the at least one geometrical parameter. The flow rate and the dosing time period are selected such that the dosing volume does not exceed the flow rate multiplied by 0.11 s.
Owner:KRUSS

Mesh network coordination system for injectable medication administration and drug interaction prevention

A mesh network medication coordination system enables communication between intelligent injection devices, monitoring systems, patient devices, or healthcare provider devices to prevent adverse drug interactions in hospital settings. The system includes mesh network infrastructure supporting multiple networked devices, dosage measurement devices that directly measure or infer dosage administration including injection completion detection, medication volume measurement, administration timing data, or patient biometric responses, or a coordination module that coordinates medication administration timing across multiple devices. The system features drug interaction analysis capabilities, real-time monitoring of patient vital signs and medication effectiveness, alert generation for potential interactions and dosing conflicts, or data synchronization across all networked devices. This integrated approach optimizes dosing intervals, prevents conflicting medication schedules, synchronizes administration events, or maintains consistent medication administration data across the mesh network to enhance patient safety and treatment efficacy.
Owner:DATADOSE LLC

Amantadine hydrochloride for the treatment of traumatic brain injury

The invention is a dosing regimen for administering an aqueous composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and a second dose of amantadine hydrochloride by intravenous injection. The first dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose comprises between 100-200 mg of amantadine hydrochloride in an aqueous solution of about 200-300 ml over a period of about two to about four hours. The second dose is administered after about four to six hours after the first dose is fully administered.
Owner:SHINKEI THERAPEUTICS INC

Smart Pill Container Device and Platform System

A smart pill container and system integrating the same, the smart pill container having a number of pill wells for storing different doses of medication according to a prescribed medical regimen, where an opening in the pill container provides at least one user with access to the medication stored in a particular one of the pill wells at a given dosing time, and where a platform associated with the pill container provides instructions for dosing such medication and monitors use of the pill container for compliance with the prescribed medical regimen.
Owner:SHARP SOLUTIONS LLC

Pudendum administration device capable of solving problems of insufficient administration due to inner wall wrinkles and incapability of quantification

InactiveCN112494790AAvoid affecting the treatment effectUniform dosingSurgeryMedical devicesTreatment effectDosing Duration
The invention relates to the technical field of medical treatment, and discloses a pudendum administration device capable of solving the problems of insufficient administration due to inner wall wrinkles and incapability of quantification. Through cooperative use of an air delivery pipe, a limiting plate, a first rotary plate and a second rotary plate, intermittent air delivery is realized duringadministration, and the wrinkles of the pudendum are supported by utilizing air pressure during administration, so that the administration is more sufficient, and the discomfort of a patient during administration is prevented from being increased by continuous air delivery; through cooperative use of a liquid storage chamber, a push rod, a swing rod, a spray pipe and a special-shaped disc, the push rod intermittently moves leftwards and rightwards in a reciprocating mode in the administration process, so that quantitative administration is guaranteed, and the administration is more uniform; the dosage can be automatically controlled, so that the situation that the treatment effect is affected due to the fact that the dosage is inconvenient to control is avoided; and through cooperative useof a first gear, a second gear and a control panel, the two steps of intermittent air delivery and quantitative dosing are linked, so that the linkage performance of the whole device is improved, andthe operation is simpler.
Owner:付鹏

Disposable pen injector with integrated logging using NFC communication

Disclosed are systems and methods for a computerized framework that electronically manages and controls a patient's therapy for proper administration of diabetic treatment. The framework includes a disposable pen injector that has integrated therein dose logging capabilities (e.g., a NFC circuit) for controlling the administration of the prescribed therapy. Electronic communications between the disposable pen injector and a therapy control application executing on a patient's device can effectuate accurate and efficient administration of prescribed therapy. The pen can communicate information to the patient's device, and the application executing thereon, that includes dosage information related to availability left in the pen, timing of doses, and the like. In a related manner, the application can compile dosage planning information that can dictate types of doses, amounts of doses, timing of doses, and the like, to ensure that the patient is complying with a prescribed diabetic prescription.
Owner:BECTON DICKINSON & CO

Accurate administration prompting system for fibroblast growth factor product after radiotherapy

The invention discloses a precise administration prompting system for a fibroblast growth factor product after radiotherapy. The system comprises a hand-held terminal which is used for collecting a time sequence image sequence, a multi-view image and individual metabolism characteristic parameters of a skin wound after radiotherapy; the control module is used for carrying out feature extraction on the time sequence image sequence according to a deep convolutional neural network based on transfer learning and outputting wound feature parameters; the wound feature parameters comprise erythema area, epidermis exfoliation rate and percolate coverage rate; wound topological structure parameters are obtained according to the multi-view image and the wound characteristic parameters; acquiring a radiotherapy period parameter corresponding to the skin wound; according to the wound feature parameters, the wound topological structure parameters, the radiotherapy period parameters and the individual metabolism feature parameters, preset administration scheme information of the fibroblast growth factor product is generated, and the administration scheme information comprises an administration time window, an administration dosage and an administration interval; and the control module sends the administration scheme information to the handheld terminal.
Owner:TIANJIN FUXUN TECH DEV CO LTD

Artificial intelligence patient guidance system for injectable medication administration

An AI patient guidance system for injectable medication administration combines intelligent injection devices with artificial intelligence guidance modules to provide real-time instructions for proper injection technique. The system includes intelligent injection devices that administer medication and collect administration data including injection completion status, dosage volume, administration timing, or patient biometric data, or AI guidance modules that provide real-time instructions, guide patients through injection site selection, needle insertion angle, injection depth, or administration timing while adapting guidance based on patient skill level and medication type. The system features machine learning modules for analyzing patient characteristics and historical patterns, patient interface modules delivering guidance through visual displays, audio instructions, haptic feedback, or augmented reality overlays, dosage verification modules, compliance scoring capabilities, adaptive learning algorithms, or confirmation systems. This comprehensive approach improves injection technique accuracy, enhances patient compliance, or ensures proper medication administration through personalized, intelligent guidance.
Owner:DATADOSE LLC

Nasal dosage forms of dihydroergotamine

PendingCN110831578AOrganic active ingredientsNervous disorderDihydroergotamineNasal dosage form
The present application relates to a nasal dosage form of dihydroergotamine, wherein the dosage form requires less than about 15 minutes for administration and requires less than four sprays to administer effective dose of dihydroergotamine for treating migraine in human subjects.
Owner:DR REDDYS LAB LTD

Drug delivery device with hidden marking

The subject invention is for use with various drug delivery devices, including medical injectors, medical pill bottles, and medical pill blister packs. The subject invention utilizes one or more optically readable codes which are initially concealed and, later revealed during or after use. The encoded data of the optically readable codes may be obtained to provide information for various purposes, including, but not limited to, verification of proper drug and dose for a given patient, dosing duration, and successful completion of dosing.
Owner:BRISTOL MYERS SQUIBB CO

Dosage supporting system and dosage supporting program

To provide a dosage supporting system and a dosage supporting program that facilitate completion of dosage of a pharmaceutical by a compression type pharmaceutical injector according to a predetermined set time.SOLUTION: A dosage supporting system 10 includes an acquisition processing unit 71 and an adjustment processing unit 72. The acquisition processing unit 71 acquires target time. The adjustment processing unit 72 adjusts an amount of infusion so as to make dosage time by a compression-type pharmaceutical injector of a prepared pharmaceutical being a mixture of a pharmaceutical and the infusion close to the target time.SELECTED DRAWING: Figure 3
Owner:YUYAMA MFG CO LTD